about
Infection with MERS-CoV causes lethal pneumonia in the common marmosetFoodborne transmission of nipah virus in Syrian hamstersEbola virus RNA editing depends on the primary editing site sequence and an upstream secondary structureNanopore Sequencing as a Rapidly Deployable Ebola Outbreak ToolEbola Laboratory Response at the Eternal Love Winning Africa Campus, Monrovia, Liberia, 2014-2015SARS and MERS: recent insights into emerging coronaviruses.Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin.Possible leap ahead in filovirus therapeutics.Dromedary camels in northern Mali have high seropositivity to MERS-CoVTreatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaquesEbola virus: unravelling pathogenesis to combat a deadly disease.A new Ebola virus nonstructural glycoprotein expressed through RNA editing.Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.Lack of protection against ebola virus from chloroquine in mice and hamstersVesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections.Natural Immunity to Ebola Virus in the Syrian Hamster Requires Antibody ResponsesA synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.Progress in filovirus vaccine development: evaluating the potential for clinical use.A Syrian golden hamster model recapitulating ebola hemorrhagic fever.The Merits of Malaria Diagnostics during an Ebola Virus Disease Outbreak.An Acute Immune Response to Middle East Respiratory Syndrome Coronavirus Replication Contributes to Viral Pathogenicity.Vaccines for viral hemorrhagic fevers--progress and shortcomingsMiddle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaquesAntiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome.Development and application of reporter-expressing mononegaviruses: current challenges and perspectives.Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model.The Ebola virus soluble glycoprotein (sGP) does not affect lymphocyte apoptosis and adhesion to activated endothelium.Assessment of Inhibition of Ebola Virus Progeny Production by Antiviral Compounds.Laboratory Response to 2014 Ebola Virus Outbreak in Mali.Plasmodium Parasitemia Associated With Increased Survival in Ebola Virus-Infected Patients.Alisporivir Has Limited Antiviral Effects Against Ebola Virus Strains Makona and Mayinga.Clinical Chemistry of Patients With Ebola in Monrovia, Liberia.Ebola vaccines: we have options.Virology. Delineating Ebola entry.Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs.Ebola sGP--the first viral glycoprotein shown to be C-mannosylated.Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus.Pathogenicity and Viral Shedding of MERS-CoV in Immunocompromised Rhesus Macaques.Regulation of endothelial barrier function during flow-induced conversion to an arterial phenotype
P50
Q21131359-7AF5FC23-380C-4873-8722-8ED21B44EE0CQ27329845-0CAB6739-2710-4A39-B379-232440E00183Q27332250-B42489A1-9264-44C5-A6C1-B9ADE9E69714Q28385526-3B84C033-61B2-4971-BDB0-B7F34DCD2277Q28390874-DFDF13A4-DDBD-4E77-8F68-2B65C3185ECCQ30249325-FD968747-D123-4506-9315-7D9D8918D143Q30429521-9194350F-2293-4003-B9A4-E779BB08C70CQ33701830-E8E4E3F9-045C-45CA-B6A1-7FF737BED9DCQ33753550-99F86D04-FAE6-4F1A-8921-FFBA629E04A2Q33887877-AEEFA776-52AE-4F94-904F-2BD85C76B172Q34514196-2C899BF5-4590-4F61-B8DC-3738772CB9AAQ34982594-2E1D7589-43F6-4729-994B-332213507039Q35300062-76ECB7A0-42B7-4F3C-9CA4-FE8B8F9AFFD9Q35673457-2E9F4053-C20C-409C-9B71-BA74373F9103Q35693152-75A3ED69-3AEA-4972-B877-F5CAFFC068FBQ36043254-23C41128-6C43-45AF-910E-1E1F8805F323Q36069589-2448F493-D4E9-4CEF-B6E2-365A7837B4E0Q36100545-691941A0-5DFF-4FC7-B1EB-A6ECF4C9A03BQ36495558-206EB139-FF8D-478E-8B66-E6E2EF5A91ECQ36525287-5BA6F8D3-3521-4202-A8EC-19D957B2EAACQ36753749-6521349E-90AC-4E3B-82F4-A1A6BE88E853Q37096221-0CC85763-7ECF-4FDE-AD77-D47EE25F5643Q37236553-3A08ED79-4D5F-4C8C-95D2-F2241BA4F550Q37263923-27909FFA-6EF5-45D9-936E-4E681BC8718AQ37690397-42ABD876-1404-4B24-B825-804C99DD674CQ39191241-B4A997EA-6DBA-4503-8880-EDA9827331A5Q39457085-5D69A7CA-D3E2-4FDE-A929-8991D6A54B25Q40054455-937A4F00-7DAB-4937-AC20-36375AA2C017Q40086261-A21B2A12-AA6B-497E-8318-22B053AE0A68Q40092348-6E80C36E-0737-4569-8845-45B3EBEFF684Q40093218-EFDB9EB7-ED2F-4175-867C-2A297AF779F8Q40094840-2C29636D-92B4-4431-AE91-4F4986B43D5DQ40124443-81F932E8-D536-4915-9877-774C475DA941Q40167735-B21925EB-39AC-4885-9688-1ABAEA982CA4Q40324973-EB3F070F-3E6E-4AD4-A86C-3DBC34ACB0F5Q40443470-5339105A-2D90-481A-9D4F-3F3C7A437D16Q40469840-DC2B6DC9-F2DB-4256-AF97-0562E2F0689FQ50289951-FD07F836-CC6F-4774-AF51-D2497F5BC7FAQ80389191-BD994B13-2734-43CF-A166-DA5BEE968737
P50
name
Darryl Falzarano
@en
type
label
Darryl Falzarano
@en
prefLabel
Darryl Falzarano
@en